Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
The advent of immune checkpoint inhibitors (ICIs) has revolutionized the field of oncology, but these are associated with immune related adverse events. One such adverse event, is myocarditis, which has limited the continued immunosuppressive treatment options in patients afflicted by the disease. P...
Main Authors: | Rishi Rikhi, Jaret Karnuta, Muzna Hussain, Patrick Collier, Pauline Funchain, Wai Hong Wilson Tang, Timothy A. Chan, Rohit Moudgil |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.721333/full |
Similar Items
-
An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
by: Roberta Esposito, et al.
Published: (2021-05-01) -
Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges
by: Martin Huertas R, et al.
Published: (2019-05-01) -
Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
by: Johnny Chahine, MD, et al.
Published: (2020-02-01) -
Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors
by: Ming Yuan, et al.
Published: (2021-10-01) -
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
by: Quentin Scanvion, et al.
Published: (2020-01-01)